Pear Therapeutics- Warrants (01/12/2026) Profit Margin

Pear Therapeutics- Warrants (01/12/2026)'s profit margin stands at 195.19% as of December 2022. That compares with -2220.12% in the prior-year period — up 108.8% year over year. That is above the sector sector average of 13.2%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Pear Therapeutics- Warrants (01/12/2026) reported 195.19% in profit margin versus -2220.12% a year earlier — a 108.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Pear Therapeutics- Warrants (01/12/2026) sits higher the its sector benchmark (13.2%) with a profit margin of 195.19%. That is roughly 1378.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 195.19% for Pear Therapeutics- Warrants (01/12/2026) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Pear Therapeutics- Warrants (01/12/2026)'s profit margin evolved across reporting periods, while the comparison chart places PEARW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.